All Stories

  1. Effects of Repeated Cisplatin and Monosodium Glutamate on Visceral Sensitivity in Rats
  2. Chemotherapy‐Induced Neuropathy Affecting the Gastrointestinal Tract
  3. The Endocannabinoid System of the Nervous and Gastrointestinal Systems Changes after a Subnoxious Cisplatin Dose in Male Rats
  4. Vitamins and fatty acids against chemotherapy-induced intestinal mucositis
  5. Content Validity of the Spanish Adaptation of the Premature Infant Pain Profile Revised
  6. From the Gut to the Brain: The Role of Enteric Glial Cells and Their Involvement in the Pathogenesis of Parkinson’s Disease
  7. Editorial: Women in gastrointestinal and hepatic pharmacology 2022
  8. Evaluation of the Effects of Instant Cascara Beverage on the Brain-Gut Axis of Healthy Male and Female Rats
  9. Contractility of isolated colonic smooth muscle strips from rats treated with cancer chemotherapy: differential effects of cisplatin and vincristine
  10. Effects of vincristine and monosodium glutamate on gastrointestinal motility and visceral sensitivity
  11. Probiotics and Probiotic-like Agents against Chemotherapy-Induced Intestinal Mucositis: A Narrative Review
  12. Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat
  13. Radiographic and histopathological study of gastrointestinal dysmotility in lipopolysaccharide‐induced sepsis in the rat
  14. New Pieces for an Old Puzzle: Approaching Parkinson’s Disease from Translatable Animal Models, Gut Microbiota Modulation, and Lipidomics
  15. Maternal Supplementation with N-Acetylcysteine Modulates the Microbiota-Gut-Brain Axis in Offspring of the Poly I:C Rat Model of Schizophrenia
  16. Radiographic assessment of the impact of sex and the circadian rhythm-dependent behaviour on gastrointestinal transit in the rat
  17. The Enteric Glia and Its Modulation by the Endocannabinoid System, a New Target for Cannabinoid-Based Nutraceuticals?
  18. Short-term stress significantly decreases morphine analgesia in trigeminal but not in spinal innervated areas in rats
  19. Cultural Adaptation and Validation of the Premature Infant Pain Profile-Revised (PIPP-R) Pain Measurement Scale: Research Protocol
  20. Editorial: Cancer therapy: The challenge of handling a double-edged sword
  21. Effects of Commercial Probiotics on Colonic Sensitivity after Acute Mucosal Irritation
  22. Lipidomics as Tools for Finding Biomarkers of Intestinal Pathology: From Irritable Bowel Syndrome to Colorectal Cancer
  23. Mechanisms of Chemotherapy-Induced Neurotoxicity
  24. Nutraceuticals and peripheral glial cells: a possible link?
  25. Cannabinoid drugs against chemotherapy-induced adverse effects: focus on nausea/vomiting, peripheral neuropathy and chemofog in animal models
  26. Molecular Targets to Alleviate Enteric Neuropathy and Gastrointestinal Dysfunction
  27. Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment
  28. Antiproliferative and palliative activity of flavonoids in colorectal cancer
  29. Coffee and Caffeine Consumption for Human Health
  30. Effects of two different acute and subchronic stressors on gastrointestinal transit in the rat: A radiographic analysis
  31. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions
  32. Nutraceuticals and Enteric Glial Cells
  33. Changes in Fatty Acid Dietary Profile Affect the Brain–Gut Axis Functions of Healthy Young Adult Rats in a Sex-Dependent Manner
  34. Dependency on sex and stimulus quality of nociceptive behavior in a conscious visceral pain rat model
  35. Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis
  36. Effects of the food additive monosodium glutamate on cisplatin‐induced gastrointestinal dysmotility and peripheral neuropathy in the rat
  37. Targeting Enteric Neurons and Plexitis for the Management of Inflammatory Bowel Disease
  38. Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis
  39. Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?
  40. Bioaccesibility, Metabolism, and Excretion of Lipids Composing Spent Coffee Grounds
  41. Changes in the diet composition of fatty acids and fiber affect the lower gastrointestinal motility but have no impact on cardiovascular parameters: In vivo and in vitro studies
  42. Radiographic dose‐dependency study of loperamide effects on gastrointestinal motor function in the rat. Temporal relationship with nausea‐like behavior
  43. Co-treatment With BGP-15 Exacerbates 5-Fluorouracil-Induced Gastrointestinal Dysfunction
  44. Fluoroscopic Characterization of Colonic Dysmotility Associated to Opioid and Cannabinoid Agonists in Conscious Rats
  45. An Assessment of the Bioactivity of Coffee Silverskin Melanoidins
  46. Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron
  47. May a sigma-1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats?
  48. Cannabinoid pharmacology and therapy in gut disorders
  49. Preclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to rats
  50. Guanylate Cyclase C: from diarrhea to cancer and beyond.
  51. Painful neurotrophins and their role in visceral pain
  52. Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?
  53. Probiotics in digestive, emotional, and pain-related disorders
  54. Young GI angle: Boosting your career development with fellowship experience
  55. Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15
  56. Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?
  57. Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons
  58. Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments
  59. Computer vision-based diameter maps to study fluoroscopic recordings of small intestinal motility from conscious experimental animals
  60. Alterations in the small intestinal wall and motor function after repeated cisplatin in rat
  61. Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat
  62. Cannabis, Cannabinoids, and Visceral Pain
  63. Cannabinoids and Effects on the Gastrointestinal Tract: A Focus on Motility
  64. Caracterización fluoroscópica en rata de la dismotilidad colónica asociada a tratamiento con morfina
  65. Cover Image
  66. Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments
  67. May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat
  68. Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease
  69. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil
  70. X-ray analysis of gastrointestinal motility in conscious mice. Effects of morphine and comparison with rats
  71. In vitroand non-invasivein vivoeffects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat
  72. Effects of chronic dietary exposure to monosodium glutamate on feeding behavior, adiposity, gastrointestinal motility, and cardiovascular function in healthy adult rats
  73. Desarrollo de miastenia gravis tras administración de toxina botulínica en el síndrome de dolor miofascial
  74. X-ray analysis of the effect of the 5-HT3 receptor antagonist granisetron on gastrointestinal motility in rats repeatedly treated with the antitumoral drug cisplatin
  75. Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy
  76. Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat
  77. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes
  78. The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility
  79. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS
  80. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors
  81. Enteric neuropathy evoked by repeated cisplatin in the rat
  82. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica
  83. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat
  84. Postnatal maturation of the gastrointestinal tract: A functional and immunohistochemical study in the guinea-pig ileum at weaning
  85. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat
  86. Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica
  87. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat
  88. Age-related changes in the gastrointestinal tract: a functional and immunohistochemical study in guinea-pig ileum
  89. 282 THE CANNABINOID AGONIST WIN 55,212-2 BOTH REVERTS AND PREVENTS SIGNS OF PERIPHERAL NEUROPATHY INDUCED BY CHRONIC CISPLATIN IN THE RAT
  90. 213 THE CANNABINOID AGONIST WIN 55,212 2 PREVENTS THE DEVELOPMENT OF MECHANICAL ALLODYNIA INDUCED BY CHRONIC CISPLATIN IN THE RAT
  91. Altered feeding behaviour induced by long-term cisplatin in rats
  92. Evaluation of the effect of age on cannabinoid receptor functionality and expression in guinea-pig ileum longitudinal muscle–myenteric plexus preparations
  93. Ileal myenteric plexus in aged guinea-pigs: loss of structure and calretinin-immunoreactive neurones
  94. Blockade of Gi/o proteins modifies electrical activity of S-myenteric neurons from guinea-pig ileum
  95. Synthesis and opioid activity of new fentanyl analogs
  96. Long-Acting Fentanyl Analogues: Synthesis and Pharmacology of N-(1-Phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides
  97. Blockade by pertussis toxin of the opioid effect on guinea pig ileum. Contractility and electrophysiological neuronal recording
  98. Calcitonin reverts pertussis toxin blockade of the opioid analgesia in mice
  99. Gene Expression of VIP Receptor in Rat Lymphocytes